title: B and T cell immunity in patients with lysinuric protein intolerance.
abstract: Lysinuric protein intolerance (LPI) is characterized by defective cellular transport of the dibasic amino acids, secondary dysfunction of the urea cycle, aversion to dietary protein, failure to thrive, hepatosplenomegaly and osteoporosis. Because several patients have suffered from recurrent respiratory infections and/or severe generalized varicella, and a few have developed systemic lupus, vasculitis or other autoimmune diseases, we have now evaluated the function of patients' immune systems. Serum concentrations of one to three IgG subclasses were decreased in 10 of the 12 patients studied. Antibody titres against diphtheria, tetanus and Haemophilus influenzae (Hib) were below the detection limit of the assay in four, three and eight of the 11 patients examined, respectively. (Re)vaccination of these 11 patients led to satisfactory responses against tetanus, but two patients still failed to develop measurable antibodies against diphtheria, two against Hib and six against one or more of the three serotypes of 23-valent pneumococcus vaccine. The proportions of T cells of all lymphocytes and the proliferative responses of the peripheral blood mononuclear cells were normal. In conclusion, humoral immune responses in some patients with LPI are defective and these patients may benefit from intravenous immunoglobulin therapy.
authors.affiliation: Department of Paediatrics, University of Turku, Finland. m.h.lukkarinen@megabaud.fi
authors.forename: M
authors.initials: M
authors.lastname: Lukkarinen
authors.forename: K
authors.initials: K
authors.lastname: Parto
authors.forename: O
authors.initials: O
authors.lastname: Ruuskanen
authors.forename: O
authors.initials: O
authors.lastname: Vainio
authors.forename: H
authors.initials: H
authors.lastname: Käyhty
authors.forename: R M
authors.initials: RM
authors.lastname: Olander
authors.forename: O
authors.initials: O
authors.lastname: Simell
mesh_terms: D000328:Adult; D000592:Amino Acid Metabolism, Inborn Errors / Q000276:immunology* / Q000628:therapy; D000641:Ammonia / Q000097:blood; D001402:B-Lymphocytes / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D007074:Immunoglobulin G / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008239:Lysine / Q000652:urine*; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology*; D014611:Vaccination
chemical_list: D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D000641:Ammonia; D008239:Lysine